Wall Street analysts predict that Protagonist Therapeutics Inc (NASDAQ:PTGX) will report earnings per share (EPS) of ($0.63) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Protagonist Therapeutics’ earnings. The highest EPS estimate is ($0.60) and the lowest is ($0.66). Protagonist Therapeutics posted earnings of ($0.57) per share during the same quarter last year, which suggests a negative year over year growth rate of 10.5%. The company is expected to announce its next quarterly earnings results on Tuesday, March 10th.
On average, analysts expect that Protagonist Therapeutics will report full-year earnings of ($2.99) per share for the current financial year, with EPS estimates ranging from ($3.01) to ($2.97). For the next financial year, analysts forecast that the business will post earnings of ($2.38) per share, with EPS estimates ranging from ($2.81) to ($2.10). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Protagonist Therapeutics.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.10. The firm had revenue of $4.14 million for the quarter, compared to analyst estimates of $5.75 million.
A number of equities research analysts recently weighed in on PTGX shares. Zacks Investment Research cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 10th. Finally, BidaskClub lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 9th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.90.
In other news, Director Bryan Giraudo bought 8,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $5.70 per share, for a total transaction of $45,600.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at $57,000. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Suneel Gupta acquired 30,000 shares of the stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $5.13 per share, for a total transaction of $153,900.00. Following the acquisition, the executive vice president now directly owns 389,824 shares in the company, valued at approximately $1,999,797.12. The disclosure for this purchase can be found here. Insiders purchased a total of 39,175 shares of company stock worth $205,493 in the last 90 days. 14.20% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in PTGX. BlackRock Inc. lifted its position in Protagonist Therapeutics by 271.6% during the second quarter. BlackRock Inc. now owns 1,017,421 shares of the company’s stock worth $12,321,000 after buying an additional 743,632 shares during the period. Millennium Management LLC grew its stake in Protagonist Therapeutics by 68.6% in the third quarter. Millennium Management LLC now owns 837,892 shares of the company’s stock worth $10,063,000 after purchasing an additional 340,892 shares in the last quarter. Vanguard Group Inc. increased its holdings in Protagonist Therapeutics by 14.4% in the second quarter. Vanguard Group Inc. now owns 800,484 shares of the company’s stock valued at $9,694,000 after buying an additional 100,960 shares during the last quarter. Renaissance Technologies LLC raised its stake in Protagonist Therapeutics by 26.5% during the second quarter. Renaissance Technologies LLC now owns 512,300 shares of the company’s stock valued at $6,204,000 after buying an additional 107,300 shares in the last quarter. Finally, Citadel Advisors LLC lifted its holdings in Protagonist Therapeutics by 12.7% during the 2nd quarter. Citadel Advisors LLC now owns 409,847 shares of the company’s stock worth $4,963,000 after buying an additional 46,120 shares during the last quarter. 79.44% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ PTGX traded down $0.10 during mid-day trading on Thursday, reaching $7.06. The company had a trading volume of 6,464 shares, compared to its average volume of 232,681. The firm has a 50 day simple moving average of $7.32 and a two-hundred day simple moving average of $10.92. Protagonist Therapeutics has a 52-week low of $4.47 and a 52-week high of $16.67. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.07. The stock has a market cap of $186.91 million, a P/E ratio of -4.05 and a beta of 1.40.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.